NCT07260578
Safety and Efficacy of Ellacor® Micro-coring® Following Best Practices on Technique and Post-Procedural Care
At risk: Primary completion moved at least 9 months later.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from May 2026 to Mar 2027 Show 4 more changesShow less
- Eligibility criteria expanded, about 8 words
- Trial status changed: Enrolling by Invitation → Active, Not Recruiting
- Study completion pushed from Jun 2026 to Apr 2027
- Secondary endpoints: details revised at 1 of 1 entry
Minor Trial status: Recruiting to Enrolling by Invitationv2 Show 4 more changesShow less
- Primary completion date: Mar 2026 to May 2026
- Study completion date: Mar 2026 to Jun 2026
- Start date changed from estimate of Dec 2025 to Nov 26, 2025
- Site details revised at 2 of 2 sites
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (1)
Arms and interventions
Alastin to be applied post procedure followed up Tegaderm. Tegaderm will be left on for 12 hours. Alastin will be applied twice daily for the duration of the study
Patients will receive Kerra+ post procedure followed by Tegaderm. The Tegaderm is removed after 12 hours. Kerra+ will be applied twice daily for the duration of the study.
Patients will receive PDGF immediately post procedure followed by Alastin followed by Tegaderm. The Tegaderm will be removed after 12 hours and the Alastin will continue to be applied twice daily for the duration of the study
Patients will receive PDGF immediately post procedure followed by Kerra+ followed by Tegaderm. The Tegaderm will be removed after 12 hours and the Kerra+ will continue to be applied twice daily for the duration of the study
Patient will only receive Tegaderm for post-care
Devices: ellacor Micro-Coring Technology
Sites
2 sites in 1 country